RedHill Biopharma Ltd.(NASDAQ : RDHL)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.23%||164.48||0.7%||$988.09m|
|MRK||Merck & Co., Inc.||0.81%||73.64||0.7%||$914.30m|
|LLY||Eli Lilly & Co.||-0.26%||231.58||1.1%||$588.95m|
|BMY||Bristol-Myers Squibb Co.||-0.61%||60.26||1.0%||$575.61m|
|CRVS||Corvus Pharmaceuticals, Inc.||-3.27%||6.80||0.7%||$140.27m|
|RPRX||Royalty Pharma Plc||-0.08%||37.10||0.1%||$121.13m|
|NVO||Novo Nordisk A/S||-1.36%||100.71||0.1%||$101.76m|
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. It operates through the following segments: Commercial Operations and the Research & Development. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Companyâ€™s subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.